WO2005084703A1 - 徐放性の口腔用組成物 - Google Patents
徐放性の口腔用組成物 Download PDFInfo
- Publication number
- WO2005084703A1 WO2005084703A1 PCT/JP2005/003978 JP2005003978W WO2005084703A1 WO 2005084703 A1 WO2005084703 A1 WO 2005084703A1 JP 2005003978 W JP2005003978 W JP 2005003978W WO 2005084703 A1 WO2005084703 A1 WO 2005084703A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- pectin
- powder
- composition according
- sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Definitions
- the present invention relates to a sustained-release oral composition containing ratatofurin that can be used in foods, medicines and the like, and a method for producing the same.
- the present invention relates to an oral composition containing ratatoferin having improved mucosal adhesion and sustained release in the oral cavity, and a method for producing the same.
- Oral diseases such as xerostomia (dry mouth), periodontal disease, gingivitis, halitosis, stomatitis, moss tongue, upper respiratory tract inflammation, and reflux esophagitis due to aging, stress, and side effects of pharmaceuticals. It has become a social problem.
- xerostomia is a general term for a condition in which the mouth is dried due to a decrease in salivary secretion (salivosis) or a withdrawal (anosaliva) due to various causes.
- salivary secretion salivary secretion
- anosaliva withdrawal
- saliva does not wash out the mouth, which can cause bad breath and make it difficult to chew and swallow smooth food.
- Stomatitis is inflammation that is observed in the oral cavity, tongue, and gums, and also occurs in patients with severe diseases, malnutrition, acute infections, and the like.
- most anticancer drugs have side effects that frequently cause refractory stomatitis, and it is said that more than 90% of patients treated with anticancer drugs suffer from stomatitis.
- Most stomatitis has the power to heal spontaneously if left unattended.
- Ratatoferrin is a glycoprotein having a molecular weight of about 80,000, which is mainly present in milk of mammals and is also found in neutrophils, tears, saliva, nasal secretions, bile, semen and the like. Ratatofeline is abundant in humans with 6-8 gZL in colostrum and 3-4 gZL in normal milk, and babies consume 2-3 g of ratatoferrin a day from breast milk. As described above, ratatoferin is considered to be very safe and a protein because there is no problem such as side effects even if a baby with weak resistance takes such a large amount.
- Ratatoferrin has the following physiological activities: antibacterial activity, iron absorption control activity, cell proliferation activity, dilation activity, hematopoietic activity, anti-inflammatory activity, antioxidant activity, phagocytosis-enhancing activity, antiviral activity, bifidobacterial growth promotion Its effects, anticancer effects, and cancer metastasis inhibitory effects are known. In addition, it has recently been reported that ratatoferin is also effective against dry mouth and xerostomia (dry eye).
- a novel pharmaceutical composition for treating stomatitis using physiological activities such as antibacterial action and antiviral action of ratatoferin
- Patent Document 1 Japanese Patent Publication No. 08-217693; Patent Document 1
- Patent Document 2 A therapeutic agent for xerostomia that promotes mucin production
- Patent Document 3 a composition for the oral cavity for treatment and prevention of periodontal disease
- Patent Document 3 a composition for the oral cavity for treatment and prevention of periodontal disease
- swallowable Novel oral cleansing composition Japanese Patent Application Laid-Open No.
- Patent Document 4 composition for oral application (Japanese Patent Application Laid-Open No. 2002-322088; Patent Document 5), powder used for oral hygiene applications (Japanese Patent Application Laid-Open No. 2003-137809; Patent Document) 6), a tablet-type dentifrice for maintaining oral health (JP-A-2004-26816; Patent Document 7) and the like have been developed and patent applications have been filed.
- Ratatoferrin is unstable to moisture and heat treatment. Therefore, when manufacturing a formulation containing ratatoferin, the wet granulation compression method generally used for tablet production is not suitable, and the direct tableting method in which the raw material is directly compression-molded in a powder state is desirable. However, it has been difficult for conventional oral patches to be formed into thin tablets by the direct compression method.
- Patent Document 1 JP 08-217693A
- Patent Document 2 JP-A-09-012473
- Patent Document 3 JP 2001-089339
- Patent Document 4 JP 2001-181160
- Patent Document 5 JP-A-2002-322088
- Patent Document 6 JP 2003-137809
- Patent Document 7 JP 2004-26816
- the present invention can be adhered to the oral cavity and is excellent in sustained release of the drug. Therefore, the active ingredient can act locally for a long time, and various Slow release for the oral cavity that can be produced by direct compression, with effective prevention and treatment of diseases, less discomfort in the mouth even after prolonged use, and less side effects
- An object is to provide a composition and a method for producing the composition.
- the present inventors have conducted intensive studies to solve the above-mentioned problems.
- the rat has a mucoadhesive property and a sustained-release property as an active ingredient, which is expected to have a prophylactic and therapeutic effect against various diseases in the oral cavity. It has been found that the above object can be achieved by combining pectic substances having the following formulas, and the present invention has been completed.
- the present invention provides:
- An oral composition containing ratatoferin which is characterized in that it contains pectic substance; a sustained-release oral composition;
- composition according to (1) wherein the pectin substance is pectin;
- composition according to the above (1) or (2) further comprising a sugar alcohol;
- composition according to any one of (1) to (3) above which is sugar alcohol power xylitol
- composition according to (1) wherein the composition is molded to a thickness of 0.5 to 2 mm.
- composition according to any one of (1) to (8) for treatment or prevention of a disease of the present invention.
- composition containing the composition according to any one of (1) to (9) and a product instruction contained in a container.
- (11) a method for producing a sustained-release oral composition, comprising mixing raw powders containing powdery ratatoferrin and powdered pectin, and subjecting the resulting powder mixture to pressure molding;
- the sustained-release oral composition of the present invention has good adhesion to the oral cavity and excellent sustained-release by containing pectin in a composition containing ratatoferin as an active ingredient. Nature can be realized. Further, according to the present invention, it is possible to reduce the thickness of the patch preparation, so that even if the preparation is applied to the oral cavity for a long period of time, the feeling of discomfort is reduced and the lactofurin is gradually released in the oral cavity. It can exert bioactivity mainly in the local area for a long time.
- ratatoferrin and pectin which are contained as essential components in the sustained-release oral composition of the present invention, have long been used as food additives for a long time, and have sufficient safety. Is secured.
- composition of the present invention that also contains a sugar alcohol has, in addition to the above effects, further improved water absorption and binding properties.
- Sugar alcohol has also been used for a long time as a food additive and is safe. Furthermore, since pectin and sugar alcohol are also dissolved in saliva, it is advantageous in that almost no solid remains.
- oral regions such as dry mouth, periodontal disease, gingivitis, bad breath, stomatitis, mossy tongue, upper respiratory inflammation, reflux esophagitis, etc.
- ratatoferin as an active ingredient exerts its effects more efficiently.
- sustained-release oral composition of the present invention can be produced by directly pressing each raw material powder by a direct tableting method without going through a granule production step, so that the moisture or heat In contrast, inactivation of unstable ratatoferin can be prevented.
- FIG. 1 is a diagram showing the effect of each adhered component on tablet thickness.
- FIG. 2 is a view showing the effect of each adhesive component on tablet hardness.
- FIG. 3 is a view showing the effect of each adhesive component on tablet mucosal adhesion.
- FIG. 4 is a graph showing the effect of xylitol content on tablet thickness.
- FIG. 5 is a graph showing the effect of xylitol content on tablet hardness.
- FIG. 6 is a graph showing the effect of xylitol content on tablet adhesion.
- FIG. 7 is a diagram showing the results of a release profile (sustained release test) of ratatofurin from tablets.
- ratatoferin refers to the power and residual of the natural ratatoferin molecule itself. It also includes functional equivalents of ratatophrine, such as recombinant ratatofurin and an active fragment of ratatofurin, regardless of the presence or absence or content of iron ions and the species of origin. "Powdered ratatoferin” refers to extra-ferric ferrin in a dry powder state.
- the average particle size of the individual ratatoferrin particles constituting the powder ratatoferrin is usually 500 m or less, preferably 1-150 ⁇ m, more preferably 1-180 ⁇ m.
- particles does not necessarily mean that the particles are spherical. Therefore, “particle size” refers to the diameter of a particle when the particle is spherical. Otherwise, it refers to the diameter of the hole through which the particle can pass. Further, the “average particle size” indicates an average value obtained by measuring the particle sizes of 10 or more particles when the particles constituting the powder vary in particle size.
- pectin refers to a plant-derived colloidal carbohydrate derivative mainly composed of galataturonan or polygalataturonic acid. And pectic acid, regardless of the plant species from which they are derived.
- pectic substances one or a mixture of two or more of the various substances exemplified above can be used.
- the pectic substance contains pectin, more preferably, at least 50% (by weight) of the components added as pectin to the composition of the present invention is pectin, most preferably, pectin. Substantially all of the components added as pectin to the compositions of the invention are pectins.
- Powder pectin refers to pectin in the form of a dry powder.
- the average particle size of the individual pectin particles constituting the powdered pectin is usually 500 ⁇ m or less, preferably 1-150 ⁇ m, more preferably 1-180 ⁇ m.
- the "sugar alcohol” is a saccharide which is hydrogenated and has a hydroxyl group, such as erythritol, xylitol, mann-tol, reduced maltose, trehalose, sorbitol, manoletitonere, isomaletitetone. , Palatinose, palatinit, and lactitonere.
- the sugar alcohol used in the present invention may be one kind or two or more kinds of various substances as described above.
- the component added to the composition of the present invention as a sugar alcohol preferably comprises xylitol.
- the sugar alcohol used in the present invention is preferably a powder, and in the present invention, the sugar alcohol in the powder is referred to as “powder sugar alcohol”.
- the average particle size of the individual sugar alcohol particles that make up the powdered sugar alcohol is usually 500 m, preferably in the range of 1-150 m, more preferably in the range of 1-180 m.
- Sugar alcohol particles such as xylitol particles are easily aggregated. Therefore, it is desirable to add a small amount of an anti-caking agent such as starch at the time of pulverization in order to prevent aggregation.
- the ratio of each of the above components constituting the sustained-release oral composition of the present invention is preferably 0.5 to 4 parts by weight of pectic substance to 1 part by weight of ratatoferrin.
- the composition of the present invention containing a sugar alcohol 0.3 to 4 parts by weight of pectin and 0.1 to 2 parts by weight of sugar alcohol are preferred with respect to 1 part by weight of ratatoferin, and most preferably ratatoferin.
- the range is 0.5 to 2.0 parts by weight of pectin and 0.2 to 1.0 parts by weight of sugar alcohol per part by weight.
- ratatoferin plays a role as an active ingredient for preventing or treating diseases in the oral region, or for preventing or treating other diseases, or generally promoting health.
- Pectin can act as an adhesive and / or gelling agent, and sugar alcohol can act as a water absorption regulator and / or binder.
- composition of the present invention may contain, in addition to these components, an active ingredient or a physiologically active substance other than ratatoferin, an adhesive other than pectic substance and a Z or gelling agent, a water absorption regulator other than sugar alcohol, and / or Binders can also be included, and further, in the field of formulation, such as functional components such as bulking agents, flavors, flavors, and coloring agents, and components necessary for the manufacturing process such as lubricants described below.
- functional components such as bulking agents, flavors, flavors, and coloring agents, and components necessary for the manufacturing process such as lubricants described below.
- additional components can be included. Those skilled in the art can appropriately select the types and amounts of these additional components.
- sustained release oral composition of the present invention can be made into tablets of any shape and size.
- the thickness of the tablet for oral application is preferably in the range of 0.5 to 2 mm.
- the horizontal hardness of the tablet (measured by the method described in Examples) is usually in the range of 1.5 to 5 kg, preferably 2 to 4 kg.
- the composition of the present invention can be formulated by any method known in the field of formulation (particularly tablet production method), but from the viewpoint of avoiding deactivation of ratatoferin, the addition of water and the heating It is advantageous to produce it by a direct tableting method that does not involve a step.
- the direct tableting method is a method in which raw material powder is pressed and compressed into an arbitrary form. For example, raw material powders containing powders of the respective components are mixed, and the powder mixture in a uniform state can be molded into a certain tablet under pressure.
- the raw material powder is preferably pulverized. This pulverization may be performed in the state of each component powder (before mixing), after mixing the components, and before pressing. You may. In the context of the present invention, pulverization refers to a process performed to equalize the size or shape of the particles constituting the powder or to reduce the particle size. It is known to those skilled in the art.
- a lubricant is generally added in order to enhance the flowability, adhesion and filling properties of the powder.
- a lubricant is generally added in order to enhance the flowability, adhesion and filling properties of the powder.
- Those skilled in the art can appropriately select a lubricant from those generally used in the tableting process in the field of formulation, and the addition concentration thereof can be adjusted to an optimum value depending on the type of the lubricant used. it can.
- the sustained-release oral composition of the present invention can be used to treat or treat diseases in the oral region such as dry mouth, periodontal disease, gingivitis, bad breath, stomatitis, mossy tongue, upper respiratory inflammation, and reflux esophagitis. Can be used for prevention. It can also be used for the prevention or treatment of other diseases for which ratatoferrin is generally effective. In addition, it can be used to take advantage of the general health-promoting effects of ratatofurin.
- the composition of the present invention can be provided as a product containing instructions for use, containing one or a fixed number in a container.
- the product can be any product such as a drug, a health food, and a luxury item, depending on the purpose of use as described above.
- the “container” may be of any material such as a bag, a box, a bottle, a can, or the like, and may be packaged by a sheet such as cellophane or paper.
- the ⁇ instruction manual '' refers to a sticker attached to a container if it contains instructions that include at least one of the use method, features, precautions, etc. of the provided product,
- the document is not limited to a written document that can be an electronic document or design.
- the sustained-release oral composition of the present invention can be used while held in the oral cavity for a long time. Therefore, the composition of the present invention can be used in the state of being placed under the tongue or the like. No. In particular, since the composition of the present invention has extremely high safety and does not have to worry about side effects, it is possible to apply a plurality of the compositions to a plurality of places at the same time, or to affix the same places continuously. It is possible.
- the amount used can be determined as appropriate according to the purpose of use, the condition to be improved, the condition of the user, etc. For example, 1 to 10 tablets per day, preferably about 1 to 5 per day, once or 2 to 5 times It can be used by dividing into about times. Further, the composition of the present invention may be used continuously, or may be used continuously at arbitrary intervals. In addition, they are used simultaneously or alternately with other medicines that can be combined with other medicines.
- the mixture was pressurized with N for 30 seconds and compression molded into a flat tablet having a diameter of 8 mm.
- Each component was pulverized in an agate mortar and then sieved with 60 mesh.
- a flat plate was prepared by adding 40 mg of tamarind gum (manufactured by Wako Pure Chemical Industries) or CMC (Ruboxymethylcellulose: manufactured by Wako Pure Chemical Industries) instead of pectin to which 40 mg was added.
- a tablet formulation was prepared. The composition of the above formulation is shown in Table 1.
- Fig. 1 shows the thickness
- Fig. 2 shows the hardness
- Fig. 3 shows the mucoadhesiveness
- Table 2 shows the test results for water absorption.
- the tablet thickness was hardly affected by the components (Figure 1), and the mucoadhesiveness of Pectin was the best ( Figure 3).
- Figure 2 CMC was the best, but CMC exerted only about half the strength of pectin, which had the worst mucoadhesiveness.
- water absorption Table 2
- tamarind gum, pectin, and CMC were listed in order of decreasing water absorption and water absorption.
- composition of the present invention containing pectin is excellent for oral application.
- Example 2 Preparation of a formulation of the present invention containing xylitol
- Example 2 Using the same method as in Test Example 1, each tablet produced in Example 2 was tested for (1) tablet thickness, (2) hardness, (3) water absorption, and (4) mucoadhesiveness. [0052] The results are shown in Fig. 416, Tables 4 and 5.
- FIG. 4 shows the results for thickness
- FIG. 5 shows hardness
- FIG. 6 shows mucoadhesiveness
- Tables 4 and 5 show results for water absorption.
- the formulation containing xylitol (DH) did not significantly differ in thickness in comparison with the formulation without xylitol (A) ( Figure 4).
- the content was high (low content of pectin)
- the hardness tended to decrease (Fig. 5, G and H).
- Mucoadhesive properties showed a tendency to decrease when xylitol was contained (low content of pectin). There was no significant difference in the amounts tested in the range tested ( Figure 6).
- the composition containing xylitol is more improved than the composition not containing xylitol, and may exhibit a water absorption comparable to or higher than that of CMC. (Table 4, G; Table 5, DG).
- compositions E and F were excellent in hardness
- the composition G was excellent in water absorption
- the compositions D, E, and F were excellent in mucoadhesiveness.
- the compositions E and F were excellent.
- the particle size of the component powder each component was sieved with 100 mesh (shown with black bars in Fig. 16). 1S was sieved with 60 mesh (shown with gray bars in Fig. 16). (Shown), hardness, water absorption, mucoadhesion, etc. It has been shown that, even when the properties are adversely changed by changing the composition, the effect can be reduced or eliminated by reducing the particle size.
- Example 2 The composition of “F” in Example 2 (1 part (25 mg) of ratatoferrin per tablet (25 mg), 1 part (25 mg) of pectin, and 0.6 part (15 mg) of xylitol) was sieved with 100 mesh.
- the release of lactofurin having a tablet strength was measured as follows.
- the measurement was carried out by a paddle method using a Japanese Pharmacopoeia 14 dissolution tester (NTR-3000; Toyama Sangyo).
- NTR-3000 Japanese Pharmacopoeia 14 dissolution tester
- 1Z15M phosphate buffer pH 6.8
- the paddle rotation speed was 60 rpm.
- 10 L of the test solution was dropped on a glass plate, and a tablet was attached. Tablets fixed on a glass plate were put into a test solution at 37 ⁇ 1 ° C, and 0.5 mL of the test solution was sampled over time, and an equal amount of the test solution at the same temperature was added.
- the lactofurin concentration in this test solution was measured using high performance liquid chromatography (HPLC).
- FIG. 7 shows the results. Ratatoferrin was gradually released over about 2 hours, confirming that the preparation of the present invention was excellent in sustained release.
- Ratatoferin (manufactured by Tatsa 'Milk' Bio-Mouth Physics Co., Ltd.) 385 g, Pectin ("Slow Set”; manufactured by Happo Shokai) 385 g, xylitol ("Xylit”; manufactured by Towa Kasei Kogyo) 230 g, sucrose fatty acid ester (Lyoichi) Tosugar ester "B-370F" (manufactured by Mitsubishi Chemical Foods) 15 g are mixed well, and a 10 mm flat tablet (thickness: about lmm) using a tabletop rotary tableting machine (RIVA) at a tableting pressure of 5 kN. ) was prepared. Ratatofurin and xylitol, after milling, As the pectin, a commercial product sieved with an 80 mesh was used.
- the prepared tablets had a hardness in the diameter direction of 2-3 kg, and showed good adhesion in the human oral cavity and almost no discomfort after the adhesion. Furthermore, the tablets attached to the oral cavity gradually dissolved and almost disappeared after about 2 hours, confirming that there was no problem with sustained release.
- Ratatoferin (Tatsa 'Milk' Bio Mouth Dix Co., Ltd.) 38.5 g, Pectin ("Slow Set”; Happo Shokai) 38.5 g, xylitol ("Xylit”; Towa Kasei Kogyo) 23 g, sucrose fatty acid Ester (Lyoto sugar ester "B-370F”; manufactured by Mitsubishi Chemical Foods Co., Ltd.)
- To prepare 1 Omm flat tablets (about lmm thick).
- Raw materials such as ratatoferrin, xylitol and pectin were all obtained by mixing commercially available powder (32-mesh sieve process) without pulverization, and then compression was performed.
- the hardness of the prepared tablet in the diameter direction was about 1 kg. For this reason, there is a concern that the product may collapse slightly during storage or transportation, but there was no particular problem with use in the oral cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510783A JPWO2005084703A1 (ja) | 2004-03-09 | 2005-03-08 | 徐放性の口腔用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-065313 | 2004-03-09 | ||
JP2004065313 | 2004-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005084703A1 true WO2005084703A1 (ja) | 2005-09-15 |
Family
ID=34918234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003978 WO2005084703A1 (ja) | 2004-03-09 | 2005-03-08 | 徐放性の口腔用組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005084703A1 (ja) |
WO (1) | WO2005084703A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008056632A (ja) * | 2006-09-01 | 2008-03-13 | Kobayashi Pharmaceut Co Ltd | 乳加工物を含有する錠剤及びその製造方法 |
JP2009234975A (ja) * | 2008-03-26 | 2009-10-15 | Fujifilm Corp | 経口物コーティング用組成物、経口物用被覆材、可食性容器およびそれらを用いた経口物 |
JP2010229036A (ja) * | 2009-03-25 | 2010-10-14 | Nipro Corp | 医薬組成物、その製造方法及び徐放性基材 |
WO2011063774A2 (en) | 2009-11-25 | 2011-06-03 | Zentiva, K.S. | Pectin complexes of steroids and pharmaceutical compositions based thereon |
WO2015020186A1 (ja) * | 2013-08-09 | 2015-02-12 | ライオン株式会社 | 錠剤組成物 |
JP5924604B1 (ja) * | 2015-04-27 | 2016-05-25 | ジャパンモード株式会社 | 口腔ケア組成物 |
JP2016210758A (ja) * | 2015-05-07 | 2016-12-15 | ジャパンモード株式会社 | 口腔ケア組成物、錠剤、顆粒状薬剤 |
JP2017007961A (ja) * | 2015-06-18 | 2017-01-12 | ジャパンモード株式会社 | 医薬品の製造方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258087A (ja) * | 1994-03-25 | 1995-10-09 | Toko Yakuhin Kogyo Kk | アロプリノール含そう剤 |
JPH09316005A (ja) * | 1996-02-19 | 1997-12-09 | Jagotec Ag | 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤 |
JP2002322088A (ja) * | 2001-04-24 | 2002-11-08 | Kakunai Juyotai Kenkyusho:Kk | 口腔貼付用製剤 |
JP2003500425A (ja) * | 1999-05-28 | 2003-01-07 | ナイドウ、エイ.サティアナラヤン | 不動化ラクトフェリン(Im−LF)抗微生物剤及びその使用 |
-
2005
- 2005-03-08 WO PCT/JP2005/003978 patent/WO2005084703A1/ja active Application Filing
- 2005-03-08 JP JP2006510783A patent/JPWO2005084703A1/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258087A (ja) * | 1994-03-25 | 1995-10-09 | Toko Yakuhin Kogyo Kk | アロプリノール含そう剤 |
JPH09316005A (ja) * | 1996-02-19 | 1997-12-09 | Jagotec Ag | 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤 |
JP2003500425A (ja) * | 1999-05-28 | 2003-01-07 | ナイドウ、エイ.サティアナラヤン | 不動化ラクトフェリン(Im−LF)抗微生物剤及びその使用 |
JP2002322088A (ja) * | 2001-04-24 | 2002-11-08 | Kakunai Juyotai Kenkyusho:Kk | 口腔貼付用製剤 |
Non-Patent Citations (3)
Title |
---|
BURGALASSI S. ET AL: "Development and in vitro in vivo testing of mucoadhesive buccal patches releasing benzydamine and lidocaine.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 133, no. 1-2, 1996, pages 1 - 7, XP002989447 * |
MIYAZAKI S. ET AL: "Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation.", INT.J. PHARM., vol. 204, no. 1-2, 2000, pages 127 - 132, XP002989448 * |
NAGGAR V.F. ET AL: "Pectin a possible matrix for oral sustained-release preparations of water-soluble drugs.", S.T.P. PHARMA SCIENCES., vol. 2, no. 3, 1992, pages 227 - 234, XP002913006 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008056632A (ja) * | 2006-09-01 | 2008-03-13 | Kobayashi Pharmaceut Co Ltd | 乳加工物を含有する錠剤及びその製造方法 |
JP2009234975A (ja) * | 2008-03-26 | 2009-10-15 | Fujifilm Corp | 経口物コーティング用組成物、経口物用被覆材、可食性容器およびそれらを用いた経口物 |
JP2010229036A (ja) * | 2009-03-25 | 2010-10-14 | Nipro Corp | 医薬組成物、その製造方法及び徐放性基材 |
WO2011063774A2 (en) | 2009-11-25 | 2011-06-03 | Zentiva, K.S. | Pectin complexes of steroids and pharmaceutical compositions based thereon |
WO2011063775A2 (en) | 2009-11-25 | 2011-06-03 | Zentiva, K.S. | Pectin complexes of sartans and pharmaceutical compositions based thereon |
WO2015020186A1 (ja) * | 2013-08-09 | 2015-02-12 | ライオン株式会社 | 錠剤組成物 |
JPWO2015020186A1 (ja) * | 2013-08-09 | 2017-03-02 | ライオン株式会社 | 錠剤組成物 |
JP5924604B1 (ja) * | 2015-04-27 | 2016-05-25 | ジャパンモード株式会社 | 口腔ケア組成物 |
JP2016210758A (ja) * | 2015-05-07 | 2016-12-15 | ジャパンモード株式会社 | 口腔ケア組成物、錠剤、顆粒状薬剤 |
JP2017007961A (ja) * | 2015-06-18 | 2017-01-12 | ジャパンモード株式会社 | 医薬品の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005084703A1 (ja) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2147227C1 (ru) | Растворяющиеся внутри ротовой полости изделия, сформованные прессованием, и способ их производства | |
WO2005084703A1 (ja) | 徐放性の口腔用組成物 | |
KR20100126266A (ko) | 약학 조성물 | |
WO2000028973A1 (en) | Process for preparing oral calcium compositions | |
AU2009284011B2 (en) | Sore throat compositions | |
IL130875A (en) | Use of an acrylic type polymer as a decomposition factor | |
JP2009544706A (ja) | 高用量の経口的に溶解可能/分解可能な凍結乾燥剤形 | |
JP2016174616A (ja) | 崩壊性組成物及び易崩壊性圧縮成型物 | |
JP4689468B2 (ja) | 錠剤およびその製造方法 | |
JPH04234324A (ja) | 咀嚼可能なスクラルフェート錠剤 | |
WO2007018057A1 (ja) | 口腔内速崩壊錠およびその製造法 | |
RU2563190C2 (ru) | Лекарственное средство на основе сухих экстрактов лекарственных растений и способ его получения (варианты) | |
CN107106640B (zh) | 含有分娩控制物质的口服崩解固体药物剂量单元 | |
JP5903250B2 (ja) | 徐放性組成物 | |
TWI343818B (ja) | ||
TW201733569A (zh) | 口腔內速崩壞性錠劑用造粒物 | |
CN103877050B (zh) | 一种维生素c可溶片及其制备方法 | |
CN101919799B (zh) | 缓释透皮给药系统 | |
JP6641626B2 (ja) | 制酸用医薬組成物 | |
US20220110900A1 (en) | Solid nutrient compositions and associated methods | |
TWI703989B (zh) | 口腔內保持型崩解性固形製劑、其製造方法、及用於該製造方法之粉體組成物 | |
JP2008133294A (ja) | 口腔内崩壊型錠剤 | |
RU2185837C2 (ru) | Биологически активная добавка "анти-пародонтит" | |
JP2003073262A (ja) | 固型製剤用包摂コーティング剤、固型製剤、その製造方法、及び食品類 | |
JPS645008B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510783 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |